[Long-term follow-up for 39 newly diagnosed diffused large B-cell lymphoma patients treated by (R)-EPOCH].
The purpose of this study was to evaluate the efficacy and safety of (R)-EPOCH protocol on patients with diffuse large B-cell lymphoma(DLBCL). From February 2004 to April 2009, a total of 39 patients who suffered from DLBCL and received (R)-EPOCH protocol were enrolled in the study. The median age of patients was 52 years old. 24 patients were on stage I/II, and 15 cases were on stage III/IV. Patients with stage I/II were administered with 4-6 cycles of (R)-EPOCH, while other patients with stage III/IV received 6-8 cycles of (R)-EPOCH. DLBCL patients with bulky disease received radiotherapy after completion of chemotherapy. 39 patients received a total of 209 cycles of chemotherapy and the median chemotherapy cycles was 6 (range, 2-8 cycles). The results showed that the overall response rate of 39 assessable patients was 87.2%, including 28 patients (71.8%) in complete remission (CR) and 6 patients (15.4%) in partial remission(PR). With a median follow-up of 57.7 months, the 1-year overall survival rate was 81.8%, while 70.9% for 3-year and 58.8% for 5-year. The major toxicity of (R)-EPOCH protocol was hematologic toxicity and the incidence of grade III-IV neutropenia and anemia were 29.2% and 14.4%, respectively. Other toxicities were mild, no treatment-related deaths occurred. At the end of follow-up,no secondary tumors occurred. It is concluded that (R)-EPOCH protocol is a effective and safe protocol for the patients with DLBCL.
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
Xiao-Yan
XY
Yang
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China. E-mail: ypzhai@medmail.com.cn.
Yong-Ping
YP
Zhai
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
Hai-Ning
HN
Liu
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
Ya-Ping
YP
Yu
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
Feng
F
Li
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province,China.
Ping
P
Song
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
Xiao-Gang
XG
Zhou
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
Zhi-Ming
ZM
An
Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
Li-Ping
LP
Wang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone